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Abstract 
This review will focus specifically on the disorders of glycogenolysis and glycolysis 
(glyco(geno)lytic) affecting skeletal muscle. McArdle disease (GSD V) is the most common 
with an estimated incidence: 1:100,000-167,000 and is caused by mutations in the gene 
encoding muscle glycogen phosphorylase. Symptoms include exercise intolerance, muscle 
contracture, muscle atrophy and weakness, acute rhabdomyolysis and risk of acute renal 
failure. Acute rhabdomyolysis (AR) is precipitated by strenuous activity and isometric 
muscle contraction, but can be prevented with appropriate advice. Individuals with GSDV 
experience a ‘second wind’ phenomenon during exercise which is characterised by abatement 
of symptoms and improved exercise tolerance after about 8-10 minutes of aerobic activity.  
Apart from branching enzyme and PGM1 deficiencies, the other muscle specific 
glyco(geno)lytic disorders present with similar symptoms to GSDV of varying severity. 
Diagnosis is frequently delayed due to their rarity and lack of access to appropriate 
investigations. Some may have additional features such as mild haemolysis, liver disease and 
neurological features. 
For all of these conditions, it seems likely that engaging with exercise will be 
beneficial resulting in improved physical capacity, reduced risk of contracture, 
rhabdomyolysis and acute renal failure; improved functionality and improved quality of life.  
There have been few randomised clinical trials, some studies have focussed on dietary 
modification although the quality of the evidence is low and no specific recommendation can 
yet be made. The development of an international registry for these disorders (EUROMAC) 
should improve our knowledge of their natural histories and provide a platform for future 
clinical trials. 
 
Key points 
 Of the glycol(geno)lytic disorders McArdle disease (GSD V) is the most common 
with an estimated incidence of 1 in 100 000-167,000 and beta-enolase deficiency the 
rarest where, currently, only 3 patients have been identified. 
 All the disorders are the result of autosomal or X linked recessive mutations resulting 
in a specific enzyme deficiency leading to the inability to utilize muscle glycogen as 
an energy substrate. 
 The main features include exercise intolerance and myoglobinuria. Most experience 
pain associated within minutes of physical activity. Risks associated with later 
development of secondary health threats from a sedentary lifestyle are common for all 
as is a reduced quality of life.  
 Additional clinical features such as dysmorphic features, haemolysis, neurological 
features, liver disease, skin lesions and or cardiomyopathy can help to pinpoint the 
specific enzyme deficiency. 
 In many cases improperly regulated physical activity can cause severe problems with 
increased risk of morbidity and mortality. Paradoxically, when appropriately 
prescribed, exercise can improve work capacity, reduce health risks, ameliorate 
symptoms and improve quality of life. 
 Research remains quite limited but treatment potential is being explored, particularly 
in McArdle disease, with the use of animal models of the disease (cattle, sheep and 
mice) and in humans through dietary manipulation and speculative drug therapy. In 
addition, a European database (EUROMAC) has been established to pool and transfer 
knowledge more effectively. 
 
Introduction 
Physical activity is inherent to the human condition and hence to normal daily 
existence for every individual on the planet. Even the most economical physical activity 
requires that skeletal muscle have adequate supplies of substrate to fuel energy demand. As a 
result, evolution has fostered the development of sophisticated energy management via 
metabolic processes whether for the most basic tasks of everyday living, such as personal 
hygiene and paid work; to achieving the pinnacle of human sporting prowess, a gold medal at 
an Olympic Games.  
Amongst Eukaryotes sexual reproduction is the major form of preserving species 
genomes and with it is the opportunity for myriad genetic mutations which have, over 
thousands of millennia, formed the basis of speciation and individual variation. A huge 
number of genetic mutations are random and arise by chance and so the outcomes lie on a 
continuum, with great advantage at one end of the spectrum (an improved ‘fit’ of individual 
to environment) and an incompatibility with life at the other.  
Mutations of genes associated with disruption or deletion of enzymes of carbohydrate 
metabolism are numerous, with some being more common than others. Most are referred to 
as glycogen storage diseases (GSDs) with a combined incidence of between 1 in 20 000 to 1 
in 43 0001. For the purposes of this review, however, only muscle disorders caused by 
enzyme deficiencies associated with glyco(geno)lysis will be considered, Table 1 provides a 
summary of the disorders covered by this review.  We will not discuss Pompe disease (GSD 
type II) as this has already been the subject of a previous review on lysosomal pathology in 
Nature Reviews2.  
Since carbohydrate is a major substrate in mammalian metabolism (the others being, 
in order of significance: lipids and amino acids), reduced access to stored carbohydrate 
results in pathologically restricted physical activity. In the context of this work, physical 
activity is considered an umbrella term, embracing all forms of activity from ‘non-exercise 
activity thermogenesis’ (NEAT)3, that activity which is incidental to everyday living, to 
‘exercise’, which, in contrast, is the deliberate, planned implementation of physical activity 
which has a defined purpose (e.g. to improve level of conditioning, and or to improve health 
status).  
The enzymatic pathways involved in glyco(geno)lysis are shown in figure 1, not only 
do deficiencies of these enzymes have implications for the capacity to carry out muscular 
work but often there are additional signs and symptoms which are specific to each condition 
which can affect function, health and future disease risks more generally. Another important 
consideration which can aid identification of these patients in the clinic is that the enzyme 
deficiency affects all skeletal muscles, thus symptoms are not confined to the legs but also 
face, neck, arms, trunk. For each specific condition there are general features which, once a 
sufficient physiological and pathological profile has been compiled, can aid diagnosis and 
subsequent management. Further complications can also exist however, as phenotypic 
variation is found and modified by epigenetic stimuli which affect expression often as a result 
of individual lifestyle choices but also by exposure to many environmental factors.  
Even for the most common of these disorders, McArdle disease (GSDV), knowledge 
and understanding is not widespread across the medical community and hence diagnosis has 
traditionally been slow with the majority of affected individuals only receiving the correct 
diagnosis on average 20 years after their first presentation to a clinician4. In childhood, 
symptoms, because of their paroxysmal nature, are commonly dismissed as ‘laziness’ by 
teachers and health professionals with the consequence that many are compelled to physical 
activities to the point of muscle damage and so are exposed to rhabdomyolysis, but also the 
difficulties of achieving these activities can result in psychological issues particularly low 
self-esteem and stigma4. Paradoxically, aerobic exercise can and should be prescribed in all 
cases of GSD as appropriate exercise prescription can improve functionality, reduce health 
risks and improve quality of life. However, knowledge and great care is required in 
prescribing exercise as mistakes can have serious and far-reaching consequences5. 
Nomenclature of GSDs generally follows two principles; named after the individual 
who first identified the disease and a GSD number based on the chronological order of their 
description. In some cases, particularly relating to exceptionally rare GSDs, the deficient 
enzyme is used.  
McArdle disease / GSD V 
This condition was first described by Brian McArdle in 1951 in a patient who failed 
to produce lactate during ischaemic exercise6 and is the result of autosomal recessive 
mutations in PYGM, the gene encoding for muscle glycogen phosphorylase7. In the UK, 
Northern Europe and USA the majority of affected  individuals have homozygous or 
compound heterozygous nonsense mutations at R50X (originally described as R49X), 
although at least 147 pathogenic mutations and 39 polymorphisms have been described so 
far8. The incidence is believed to be in the region of 1:100 000-1:167,000, although accurate 
epidemiological data are lacking9,10. In affected people there is absence of enzyme muscle 
glycogen phosphorylase, which normally catalyses the conversion of muscle glycogen to 
glucose-6-phosphate in the Embden-Myerhof-Parnas (glycolytic) pathway (figure 1). 
Interestingly, patients with a rare splice site mutation resulting in a small amount of residual 
enzyme (1-2.5%) have been described with a milder phenotype evident with exercise 
testing11 This suggests that only very low levels of PGM are sufficient to ameliorate 
symptoms- an important observation for possible therapeutic strategies in the future. 
Since typically, 503g of carbohydrate is available for use in those without pathology: 
400g muscle glycogen, 100g liver glycogen and 3g of glucose circulating in the blood stream, 
people with McArdle disease have access to just 20% of that carbohydrate in comparison 
with healthy individuals12 (Figure 2). As a consequence there is abnormal storage of muscle 
glycogen in sub-sarcolemmal vacuoles seen on muscle histology. Histochemistry shows 
absence of the enzyme muscle glycogen phosphorylase apart from residual staining in smooth 
muscle on blood vessels of the brain/foetal isoform (Figure 3).  
At the start of aerobic exercise, such as walking, muscle contraction is fuelled by ATP 
already attached within the muscle fibre. ATP is hydrolysed to ADP, the breaking of a 
phosphate bond providing the free energy (ΔGo) for the ‘power stroke’, with actual 
movement seen in the shortening of the sarcomere (‘sliding filament theory’, the accepted 
mechanism of muscle contraction13,14). ADP is reconstituted from intramuscular stores of 
creatine phosphate by donation of Pi. However, this process is soon outstripped by demand 
and since, in people with McArdle disease, other sources are not yet available leading to an 
energy crisis causing the heart rate to increase sharply together with symptoms of discomfort 
and fatigue in the exercising muscle. This requires the individual to slow down or to stop the 
activity, allowing symptoms to subside or disappear before exercise can continue. Upon 
recommencing activity, symptoms may again appear but should soon diminish, alongside a 
decrease in heart rate (at between 8-10 minutes into continuous physical activity), as a result 
of the increased supply of ATP associated with increased efficiency of fat oxidation and 
improved muscle blood supply. The lag is created by the time taken to increase the rate of fat 
oxidation to an appropriate level to meet a relatively modest demand, with respect to intensity 
of effort. The abrupt easing of symptoms and attendant, sudden increase in exercise capacity, 
is known as the ‘second wind’ phenomenon15 and is a specific characteristic of this condition 
and so is considered pathognomonic for McArdle disease16. In McArdle disease, blood 
lactate, which is an obligate feature of normal physiology associated with increasing exercise 
intensity, fails to rise compared with normal healthy individuals. Lactate itself represents a 
highly significant fuel source during exercise17,18 (Figure 4) which is, of course, lacking in 
this patient population. 
Without careful management during the early stages of physical activity to ensure that 
the second wind is achieved, there is a significant risk of contracture and rhabdomyolysis.  
Muscle contracture is a type of muscle cramp which is electrically silent19 and is common in 
McArdle disease leading to muscle damage and rhabdomyolysis4. As a consequence, when 
performing exercise assessments in this patient population, on either an exercise bike20, 
treadmill or corridor using a 12 minute walk test (12MWT)21  heart rate is generally 
monitored alongside the use of the CR10 pain rating scale (RPP) or Borg rating of perceived 
exertion (RPE)22.   
The 12MWT is a useful measure that can be done in a clinic setting without the need 
for specialist equipment. Immediately prior to commencing the test, the RPP scale is 
explained to the patient, to anchor the ends of the range descriptors. During exercise testing, 
efforts are made to ensure that pain does not exceed a rating of ‘4’, as levels above this are 
much more consistent with the onset of muscle contracture. Testing of this type should occur 
on a regular basis for clinical monitoring, with the total distance walked being recorded as an 
outcome measure of current level of function and to monitor improved function between 
successive test periods. By monitoring the heart rate each minute during the test, the second 
wind is often evident21. A functional cycle test can also be very useful for monitoring 
patients, but requires specialist equipment and trained staff, however, it provides a highly 
useful and validated outcome measure for research studies20. 
Optimum clinical management includes exercise prescription designed to increase 
both function and capacity for physical activity whilst minimising acute risk of contracture. 
The long-term objective being increased ease of daily function with lower health risk and 
subsequent improved quality of life. This can be achieved by instructing patients on how to 
reach a second wind for each muscle group that is to be used subsequently, and the setting of 
short terms goals. The first major aim being to comply with the minimum recommended 
guidelines for exercise for health of 150 minutes per week, distributed as five days per week 
at moderate intensity23,24. The benefits of regular exercise are well known and higher levels 
of physical conditioning (‘fitness’) are highly correlated with reduced health risks25,26 and 
improving physical conditioning by even very modest amounts (1ml/kg/min improvement in 
VO2max27,28 or 1 MET improvement in exercise capacity29) can result in a 10-12% reduction 
in health risks and all-cause mortality. 
Exercise and McArdle Disease 
Where there is little doubt that physical activity and exercise is beneficial, the 
perceived risk of moderate to high intensity exercise amongst these patients is high and the 
suggestion that it may be possible to exercise at higher intensities and to include resistance 
exercise (weight training) is contentious because of the high risk of acute rhabdomyolysis, 
however, resistance training albeit with close supervision, has been successfully achieved in 
people with McArdle disease30.  
In a number of other pathologies (e.g. heart disease, type II diabetes) higher intensity 
exercise (particularly aerobic high intensity interval exercise) is increasingly demonstrated to 
be efficacious for amelioration of symptoms and in improving function31-36. For many years 
testing the VO2peak (maximal oxygen uptake) of people with McArdle disease was generally 
considered impossible for fear that the required high intensity of effort would increase the 
incidence of adverse events such as contracture, rhabdomyolysis, renal failure and attendant 
increased mortality risk. However, in Spain testing of VO2peak in people with McArdle 
disease has occurred since 2006 and is challenging this perception. Data collected on 81 
participants all with a diagnosis of McArdle disease have found positive significant 
correlations when comparing cardiorespiratory fitness (VO2peak) with quality of life and an 
inverse relationship with severity of impairment37. This suggests that people with McArdle 
disease benefit generally by being sufficiently active to improve cardiorespiratory 
conditioning and some may adapt to be able to tolerate higher intensity efforts and so further 
reduce risks associated with their pathology.  
A study of eight participants with McArdle disease training at 60-70% of peak heart 
rate during cycling sessions lasting 30-40 minutes for 14 weeks demonstrated a 36% 
improvement in peak work capacity, as well as improvements in peak cardiac output, and 
indicators of improved muscle oxidative capacity, increased citrate synthase and beta-
hydroxyacetyl CoA dehydrogenase38.       
The consensus on resistance training (using weights) is generally a negative one for 
this population but research evidence contradicts this perception. Santalla et al39 recently 
conducted (2014) a four month resistance training programme using 7 adults confirmed to 
have McArdle disease by genetic testing. Participants trained twice a week at the same venue 
and were always supervised and had undergone two sessions of instruction to ensure they 
could safely undertake weight lifting. Power velocity curves were constructed for each 
patient for half squat (lower body assessment) and bench press (upper body assessment) 
before and after the 4-month training intervention. A significant improvement in lean mass 
was noted (P<0.05) and significant improvements in muscle strength for both upper and 
lower extremities (bench press improved by 52W, 95% CI: 13, 91 and half squat improved by 
173W, 95% CI: 96, 251) was demonstrated without any serious adverse events. As a 
consequence in this study, all patients saw a change to a lower severity class for their disease. 
Clinical improvements persisted even after a detraining period with all participants being 
classed as mild for disease severity. This suggests that addition of resistance training could be 
an extremely useful adjunct to aerobic exercise, since one of the consequences of having 
McArdle disease is that increasing muscle mass is difficult. As a consequence with advancing 
age there is muscle atrophy and weakness especially involving shoulder girdle and paraspinal 
muscles, in addition, semi-acute muscle atrophy following injury may be permanent. The 
proviso however, is the use of appropriately qualified and experienced staff being available to 
closely supervise every training session. This approach, however, would have significant 
financial and staff resource implications.  
Basic and applied research 
A number of approaches have been undertaken with respect to potential treatment of 
McArdle disease including dietary manipulation and invasive research intervention using 
animal models for the disease40,41.  
Diet 
Creatine supplementation has been used to enhance purine nucleotide cycling but, 
although it did increase CK activity in patients, in high dose, it caused increased pain and 
inhibited tasks of everyday living40 and subsequent consensus was of no clinical benefit41. 
Ingestion of sucrose (75g in 660ml solution, 40min before exercise) increased blood 
glucose by more than 2 mmol·L-1 and resulted in a large reduction in RPE and a reduction in 
heart rate of 34 bt·min-1 during exercise on a cycle ergometer42. Further studies confirmed 
that sucrose or fructose can improve exercise tolerance and capacity, increases well-being 
and may reduce the risk of exertional rhabdomyolysis42,43,44. 
Since people with McArdle disease cannot access the majority of their endogenous 
carbohydrate stores and because they have ‘exaggerated’ lipid oxidation45 there has been 
speculation as to the potential benefits of a ketogenic diet46. Indeed, there are anecdotal 
reports from individual patients who have tried it themselves who report improved exercise 
capacity and reduced incidence and magnitude of symptoms. Further studies including 
randomised controlled trials are now required to objectively test these subjective findings. 
Animal models 
A number of animal models are available for further research on the potential to treat 
McArdle disease including bovine, ovine and murine models47. A study using notexin, a 
myotoxin derived from the venom of the Australian tiger snake (Notechis scutatus) was 
injected into the muscle of live sheep. Muscle biopsies were taken pre and 21 days post 
injection and compared with untreated sheep muscle. Notexin initially caused muscle 
necrosis followed by regeneration with some fibres expressing both non-muscle isoforms of 
phosphorylase (brain/fetal and liver) with resultant increased force of muscle contraction and 
reduced fatigue. The authors concluded that future research should further examine the 
potential of re-expression of these isoforms as a treatment for McArdle disease48. More 
recently, sheep were given sodium valproate, administered systemically by enteric route, this 
drug normally used for the treatment of epilepsy has HDAC qualities which might potentially 
affect chromatin and gene expression. Although mobility was unaffected re-expression of 
phosphorylase did occur in a dose-dependent manner reaching a peak in 2 hours and so 
suggests another possible avenue of investigation for treatment of human McArdle disease49. 
Cori Disease / Forbes Disease / GSD type III 
This disorder is the result of autosomal recessive mutations of the AGL gene, which 
result in deletion of the enzyme, amylo-1,6-α-glucosidase, 4-α-glucotransferase (more 
commonly referred to as ‘debranching enzyme’) with an incidence of less than 1 in 100 000. 
There are four subtypes (types IIIa, IIIb, IIIc and IIId) and their existence and the consequent 
variation in symptoms is explained by tissue differences in enzyme expression. The majority 
of affected people lack the enzyme in both muscle and liver (type IIIa) with only around 15% 
lacking it in liver only (type IIIb)50. Deficient enzyme in cardiac muscle leads to late onset 
cardiomyopathy51,52,53.  
The usual presentation is in infancy or early childhood with hepatomegaly, 
hypoglycaemia, and growth retardation which improves with age. However, in type IIIa 
progressive skeletal muscle atrophy and weakness together with cardiomyopathy develops in 
adulthood. Serum CK is raised and muscle biopsy shows abnormal glycogen storage50. 
Although diagnosis can be confirmed without muscle biopsy by measuring enzyme levels in 
red blood cells and confirmatory DNA studies54. Exercise intolerance is a function of both 
muscle weakness (mainly arising from atrophy and fatigue) and energy deficiency. The 
energy deficiency arises from the inability to debranch glycogen55, which is partially 
compensated for by increased lipid oxidation as elucidated by isotopic labelling56 but also 
from altered peripheral blood flow which contributes to a slowing of recovery57. 
Tarui Disease / GSD type VII 
Named after the Japanese physician Seiichiro Tauri who first identified 
phosphofructokinase (PFK) deficiency in 196558, this disorder is generally the result of 
mutations in the PFK-M gene, although since PFK comprises three distinct subunits each 
encoded by a different gene, mutations associated with PFK-L (liver) and PFK-P (platelet) 
genes are also possible59,60.  In common with other glycolytic disorders symptoms are of pain, 
exercise intolerance, muscle contracture and rhabdomyolysis. Although exercise intolerance 
tends to be more severe than in McArdle disease and there is no second wind reported. 
Indeed patients describe an ‘out of wind’ phenomenon whereby the administration of glucose 
prior to exercise worsens exercise capacity by ‘blocking’ fatty acid oxidation. One interesting 
reported phenomenon is the development of nausea and vomiting with exertion, this is not 
described in any of the other related glycolytic disorders.  In addition, the glycolytic pathway 
in red blood cells is affected as a consequence of disrupted Ca2+ homeostasis and so a specific 
feature of the condition is mild compensated haemolysis61. As in McArdle disease, 
hyperuricaemia and gout are also common features. Fixed muscle weakness is common with 
advancing age and a specific phenotype mimicking limb girdle muscular dystrophy has been 
reported. A fatal infantile form associated with arthrogryposis and brain malformation has 
been reported, but appears to be a distinct genetic entity62. 
 Tarui disease is a very rare condition with only around 100 patients so far reported in 
the literature it is more prevalent amongst those of Ashkenazi Jewish origin and or those of 
consanguineous heritage63. The disease is more common in dogs64 which may therefore 
represent a good animal model for future study.   
Prescription of exercise in this population is also likely to be beneficial although there 
have been no clinical trials. In this population, more frequent pauses are likely to be required 
and the ‘second wind’ phenomenon, so characteristic of McArdle disease, is absent. Exercise 
prescription must be much more tailored to this condition and thus, from our own experience, 
the best advice may be ‘little and often’. In practice, this may mean utilising stored ATP 
during very short bouts of exercise with intervals of only six seconds at a time before 
implementing a short a rest of 10-20s, this strategy, used in our clinical practice is based upon 
established doctrine in sports and exercise physiology whereby 6-10 seconds worth of stored 
ATP could be utilised for bursts of energy. Whether or not this exercise format imposes 
sufficient appropriate stimuli (of both intensity and or duration) to encourage beneficial 
adaptation, in terms of both function and reduced risk of secondary diseases of hypokinesis 
(such as type II diabetes and heart disease), is unknown. This could, however, be an area of 
further research to determine acute responses and identify any chronic adaptation which may 
improve function and quality of life. 
Glycogen phosphorylase b kinase deficiency / GSD type IX 
This disorder is often described as being ‘at least four different conditions’ (GSD 
types IXa, IXb, IXc and IXd) and is related to the fact that the enzyme is a tetramer of four 
protein subunts (α, β, γ and δ) each being encoded by a separate gene. The overall incidence 
of type IX is around 1 in 100,000 65 and is characterised by deficiency of the enzyme 
phosphorylase b kinase in muscle and or liver. The normal function of this enzyme being to 
convert the inactive form of phosphorylase (phosphorylase a) to it’s active form 
(phosphorylase b).  
The condition was first described in the 1960s66 and involves mutations of the 
PHKA1, PHKA2, PHKB or PHKG2 genes and is subject to autosomal recessive or X-linked 
inheritance67. Since females have two X chromosomes but one is subject to ‘X-
inactivation’68, which is in itself random such that, some cells have one of the Xs activated 
whilst others have the other one inactivated, it is extremely difficult to predict expression or 
anticipate symptoms as a multitude of permutations is possible. Females with a disease gene 
on one X chromosome are carriers of the disease but only experience symptoms of the 
disease themselves if the mutated gene is the one which is active in a larger percentage of 
cells69. For both manifesting carriers and those inheriting the condition, there is considerable 
genetic variation which greatly increases the range of possible phenotypic expression. 
Accordingly, symptoms can range from mild to severe. 
Common symptoms of the liver form include hepatomegaly, hypoglycaemia during 
fasting and growth impairment70. The muscle form of the condition is much rarer and very 
infrequently reported, making characterisation extremely difficult. 
ß-enolase deficiency/ GSD type XIII 
This is a very rare, and only very recently reported, disorder of the catalysis between 
2-phosphoglycerate and phosphoenol pyruvate (intermediaries of the Embden-Meyerhof-
Parnas pathway) and was first reported by Comi et al in 200171. Only two papers have been 
published describing just three patients in total71, 72. Autosomal recessive mutations in ENO3 
are responsible for the documented cases to date72, however, other gene mutations may be 
possible as beta-enolase comprises three subunits (α, ß, and ϒ ) each encoded by different 
genes. The α subunit has been identified in many different tissues whilst ß is mostly found in 
muscle and ϒ in nervous tissue73.  
The condition is milder than McArdle disease and symptoms include exercise 
intolerance, myalgia, contracture, generalised muscle weakness after exercise, hyperCKaemia 
and myoglobinuria although onset of symptoms is hard to define as in one individual 
significant problems (substantial rhabdomyolysis) were not reported until middle age whilst 
another patient reported problems since childhood71. With the advent of next generation 
sequencing to aid diagnosis, it seems likely that milder disorders such as this will be shown to 
be more common than previously thought, our centre has just diagnosed a second patient 
within 18 months of the first described in Masumeci et al 72. However, with so few patients 
identified to date, the clinical picture for ß-enolase deficiency has yet to be fully elucidated. 
PGM1 deficiency 
PGM1 deficiency has been described as a cause of exercise intolerance and 
rhabdomyolysis in adults74, but a novel presentation of this Glycogen storage disorder was 
identified by chance as part of an exome sequencing project to identify the causative mutation 
in a number of individuals thought to have a disorder of glycosylation75. PGM1 catalyzes the 
bidirectional transfer of phosphate from position 1 to 6 on glucose. Glucose-1-P and UDP-
glucose are closely linked to galactose metabolism, thus all of the patients had abnormal 
transferrin glycoforms. Clinical features included dysmorphic features including cleft palate 
and bifid uvula, short stature, and accessory thumbs. Other features included a raised CK, 
myopathy, rhabdomyolysis liver disease and cardiomyopathy74. Galactose supplementation, 
at least in vitro has been shown to correct the defect in glycosylation and thus offers a 
potential therapeutic strategy as yet to be tested in patients75,76. 
Other rare related glycolytic disorders 
The remaining disorders in the glycolytic pathway are extremely rare, all present in a 
similar way with exercise intolerance with/or without episodes of rhabdomyolysis. 
Phosphoglycerate mutase is caused by autosomal recessive mutations in PGAM2 and there 
may be an associated finding of tubular aggregates in muscle biopsy77,78. The majority (9/14) 
of affected individuals reported so far are of African American descent, symptoms are 
relatively mild compared with McArdle disease and are induced only by strenuous physical 
exertion79,80.  
Phosphoglycerate kinase deficiency has been reported in males presenting with 
haemolytic anaemia with or without neurological features including parkinsonism and/or 
learning difficulties and myopathy with exercise intolerance81,82,83. Inheritance is sex linked 
recessive. In one case the haemolytic anaemia was severe enough to warrant blood 
transfusion at a young age before the onset of myopathic symptoms84. 
Lactate dehydrogenase A subunit deficiency was first reported in 1980 and is very 
rare with only nine families reported world-wide, six of whom are of Japanese origin. It 
presents with exercise intolerance and myoglobinuria and in some patients there are typical 
skin lesions85,86, 87.  
 Summary and conclusions 
 In summary, disorders of glyco(geno)lysis are associated with exercise induced 
symptoms occurring within a few minutes of aerobic activity, an inability to perform 
isometric muscle activities and a risk for muscle contracture and acute rhabdomyolysis with a 
risk of acute renal failure. The presence of additional features such as haemolytic anaemia, 
neurological, skin, hepatic and/or cardiomyopathy can point to specific enzyme deficiencies 
and aid diagnosis. There is no specific treatment for any of these disorders but aerobic 
training with exercise prescription is important for improving fat oxidation through 
conditioning and reducing the attendant health risks of a sedentary life style. Due to the rarity 
of these disorders there remain questions about natural history and long term consequences of 
a sedentary life-style. In 2015 a registry, funded by the European Union, was established 
(www.euromacregistry.eu) which, it is hoped, will provide useful data on the prevalence and 
natural history of these disorders as well as providing a platform for future clinical trials88. 
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Figure 1 
 
 
Figure 2 
  
In individuals without pathology carbohydrate is distributed as 400g of glycogen in muscle, 
100g of glycogen in liver and 3g of glucose in the systemic circulation. In McArdle patients > 
400g is stored in muscle, but is unavailable as a fuel substrate with only liver glycogen and 
blood glucose being available for metabolism. 
 
 
 
  
Figure 3 
  
Muscle biopsy from a patient with McArdle disease, a) H&E illustrating sub-sarcolemmal 
vacuoles with excess glycogen storage b) absent staining of muscle glycogen phosphorylase 
which is seen only in the smooth muscle of blood vessels (foetal/brain isoform). 
 
Figure 4 
Blood lactate concentration with exercise  
 With increasing exercise intensity healthy individuals without pathology demonstrate a rise in 
blood lactate concentration. In contrast, people with McArdle disease have a normal resting 
blood lactate concentration but this decreases at the start of exercise and remains low 
throughout despite increasing exercise intensity. 
 
Table 1 
Skeletal muscle disorders of Glyco(geno)lysis covered by this review 
Enzyme Gene Inheritance Features 
Phosphorylase 
deficiency 
PYGM AR Exercise intolerance, myoglobinuria, second 
wind,  
Skeletal muscle atrophy  
and weakness, gout 
Amylo-1,6-α-
glucosidase, 4-α-
glucotransferase 
AGL AR Type IIIa skeletal and cardiac muscle atrophy 
and weakness,  
IIIc skeletal/cardiac muscle and 
liver, types IIIb and IIId liver only 
Phosphofructokinase 
deficiency 
PFKM AR Vomiting with exercise, exercise intolerance,  
Myoglobinuria, muscle atrophy and 
weakness, gout,  
haemolytic anaemia. Neonatal form with 
arthrogryposis 
Phosphorylase B kinase PHKG1 AR ? 
 PHKA1 AR Exercise intolerance 
myoglobinuria 
 PHKA2 XL Liver disease exercise intolerance and 
myoglobinuria 
 PHKB XL Liver disease, exercise intolerance and 
myoglobinuria 
 PRKAG2 AR WPW syndrome,  
Hypertrophic cardiomyopathy 
Phosphoglucomutase 1 PGM1 AR Dysmorphic syndrome (short stature, 
cleft palate, bifid uvula), exercise intolerance 
and myoglobinuria 
dilated cardiomyopathy, liver disease 
abnormal transferrin  
glycoforms 
Phosphoglycerate 
mutase 
PGAM2 AR Exercise intolerance 
myoglobinuria 
Tubular aggregates in muscle biopsy 
Phosphoglycerate 
kinase 
PGK XL Exercise intolerance  
myoglobinuria 
Haemolytic anaemia, 
Learning difficulty, parkinsonism 
Lactate dehydrogenase LDHA AR Exercise intolerance, 
myoglobinuria,  
Skin rash 
 
 
 
